EUCTR2016-003069-25-CZ进行中（未招募）1 期
A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF) - ELIMINATE-AF
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 560
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female at least 18 years of age with documented history of paroxysmal (lasting =7 days), persistent (lasting >7 days but =12 months) or long-standing [long-lasting] persistent (>12 months) non-valvular AF. Duration of AF can be confirmed by any electrical tracing or a recording in the subject’s medical records (e.g., medical chart, hospital discharge summary).
- •2.Subject is eligible and is scheduled for either radiofrequency (RF) or cryoballoon catheter ablation (both first and repeated procedure included).
- •3.Signed ICF.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 260
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 300
排除标准
- •1.AF considered to be of a transient or reversible nature (such as in myocarditis,post-surgery,ionic disturbances,thyrotoxicosis,pneumonia, severe anemia etc.)
- •2.Subject post stroke,or with a systemic thromboembolic event within the past 6 months prior to randomization
- •3.Subject has a thrombus in the left atrial appendage,left atrium,left ventricle, or aorta,or an intracardial mass
- •4.Subject had a myocardial infarction(MI) within the 2 months prior to randomization or coronary artery bypass graft surgery within 3 months prior to the randomization
- •5.Subject has signs of bleeding, history of clinically-relevant bleeding according to ISTH,or conditions associated with high risk of bleeding such as past history of intracranial,or spontaneous intraocular,spinal,retroperitoneal,or intra-articular bleeding; overt gastrointestinal bleeding or active ulcer within the previous year;recent severe trauma,major surgery,or deep organ biopsy;active infective endocarditis;uncontrolled hypertension (blood pressure [BP] above 170/100 mmHg);or hemorrhagic disorder including known or suspected hereditary or acquired bleeding or coagulation disorder in the last 12 months prior to randomization
- •6.Subjects with mechanical heart valves,subjects with moderate to severe mitral stenosis and subjects who have new implantation of a bioprosthetic heart valve, with or without AF
- •7.Subjects with a history of LAA occlusion/exclusion
- •8.Subjects with any contraindication for edoxaban,VKA,low molecular weight heparin,heparin therapy, including known allergies,hypersensitivity,or intolerance to any component of these drugs or its excipients
- •9.Subjects receiving dual antiplatelet therapy(DAPT, i.e., aspirin and P2Y12 antagonist) or planned to receive DAPT during the study
- •10.Unfractionated heparin,low molecular weight heparins,heparin derivatives(fondaparinux, etc.), and oral anticoagulants(warfarin,dabigatran etexilate,rivaroxaban,apixaban etc.)should not be used concomitantly to study medication.Any bridging with LMWH around the CA procedure is prohibited.During the CA procedure,UFH will be used according to standard of care to achieve ACT of 300 to 400 sec.Subjects who require chronic use of medicines affecting hemostasis such as higher doses of aspirin(ASA up to 100 mg per day allowed) or chronic oral or parenteral intake of non-aspirin non-steroidal anti inflammatory drugs (NSAID) on =4 days/week
- •11.Subjects with active liver disease or persistent elevation of liver enzymes/bilirubin:
- •?Alanine transaminase or aspartate transaminase =2 times the upper limit of normal
- •?Total bilirubin (TBL) =1.5 times the ULN (subjects whose elevated TBL is due to known Gilbert’s syndrome may be included in the study)
- •?Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
- •12.Subjects with kidney failure (creatinine clearance <15 mL/min)
- •13.Subjects with hemoglobin <10 g/dL or platelet count <100,000 cells/µL or white blood cell count <3000 cells/µL
- •14.Subjects with pre-planned invasive diagnostic or therapeutic procedures/interventions(other than endoscopy) during the study period in which bleeding is anticipated
- •15.Participation in any other interventional trial(subjects who received any investigational drug or device within 30 days prior to randomization,or plan to receive such therapy during the study period)
- •16.Previous randomization in this study
- •17.Female subjects of childbearing potential without using highly effective contraception
研究者
相似试验
进行中（未招募）
1 期
Edoxaban treatment versus anticoagulant treatment (here Vitamin K antagonist) in patients with atrial fibrilation undergoing a catheter ablatioSubjects undergoing catheter ablation of non-valvular atrial fibrillationMedDRA version: 20.0 Level: PT Classification code 10003658 Term: Atrial fibrillation System Organ Class: 10007541 - Cardiac disordersEUCTR2016-003069-25-DEDaiichi Sankyo Europe GmbH560
进行中（未招募）
1 期
Edoxaban treatment versus anticoagulant treatment (here Vitamin K antagonist) in patients with atrial fibrilation undergoing a catheter ablatioSubjects undergoing catheter ablation of non-valvularatrial fibrillationMedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2016-003069-25-PLDaiichi Sankyo Europe GmbH560
进行中（未招募）
1 期
Edoxaban treatment versus anticoagulant treatment (here Vitamin K antagonist) in patients with atrial fibrilation undergoing a catheter ablatioSubjects undergoing catheter ablation of non-valvularatrial fibrillationMedDRA version: 19.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2016-003069-25-ESDaiichi Sankyo Europe GmbH560
进行中（未招募）
1 期
Edoxaban treatment versus anticoagulant treatment (here Vitamin K antagonist) in patients with atrial fibrilation undergoing a catheter ablatioSubjects undergoing catheter ablation of non-valvular atrial fibrillationMedDRA version: 20.0 Level: PT Classification code 10003658 Term: Atrial fibrillation System Organ Class: 10007541 - Cardiac disordersEUCTR2016-003069-25-GBDaiichi Sankyo Europe GmbH620
进行中（未招募）
1 期
Edoxaban treatment versus anticoagulant treatment (here Vitamin K antagonist) in patients with atrial fibrilation undergoing a catheter ablatioSubjects undergoing catheter ablation of non-valvularatrial fibrillationMedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2016-003069-25-ITDAIICHI SANKYO EUROPE GMBH602